Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

References

• Löwenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program. 2008;1–11.
   PubMedGoogle Scholar
• Megías-Vericat JE, Montesinos P, Herrero MJ, et al. Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics. 2016;17:1245–1272.
   PubMed Web of Science ®Google Scholar
• Kim KI, Huh IS, Kim IW, et al. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer. 2013;49:403–410.
   PubMed Web of Science ®Google Scholar
• Wan H, Zhu J, Chen F, et al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res. 2014;33:90.
   PubMed Web of Science ®Google Scholar
• Shi JY, Shi ZZ, Zhang SJ, et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics. 2004;14:759–768.
   PubMedGoogle Scholar
• Amaki J, Onizuka M, Ohmachi K, et al. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol. 2015;101:543–553.
   PubMed Web of Science ®Google Scholar
• Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia. 2009;23:1929–1932.
   PubMed Web of Science ®Google Scholar
• Xu PP, Chen BA, Feng JF, et al. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Chin Med J (Engl). 2012;125:2137–2143.
   PubMed Web of Science ®Google Scholar
• Falk IJ, Fyrberg A, Paul E, et al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase. Am J Hematol. 2013;88:1001–1006.
   PubMed Web of Science ®Google Scholar
• Yee SW, Mefford JA, Singh N, et al. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013;58:353–361.
   PubMed Web of Science ®Google Scholar
• Medina-Sanson A, Ramírez-Pacheco A, Moreno-Guerrero SS, et al. Role of genetic polymorphisms of deoxycytidine kinase and cytidine deaminase to predict risk of death in children with acute myeloid leukemia. Biomed Res Int. 2015;2015:309491
   PubMed Web of Science ®Google Scholar
• Bhatla D, Gerbing RB, Alonzo TA, et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009;144:388–394.
   PubMed Web of Science ®Google Scholar
• He H, Liu ZQ, Li X, etet al. The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia. J Clin Pharm Ther. 2015;40:555–560.
   PubMed Web of Science ®Google Scholar
• Hyo Kim L, Sub Cheong H, Koh Y, et al. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet. 2015;60:749–754.
   PubMed Web of Science ®Google Scholar
• Cao X, Mitra AK, Pounds S, et al. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013;14:1449–1466.
   PubMed Web of Science ®Google Scholar
• Braunagel D, Schaich M, Kramer M, et al. The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia. Leuk Lymphoma. 2012;53:952–957.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. JCO. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Colovic N, Tomin D, Vidovic A, et al. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. Biomed Pharmacother. 2012;66:578–582.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res. 2002;26:621–629.
   PubMed Web of Science ®Google Scholar
• Banklau C, Jindadamrongwech S, Sawangpanich R, et al. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol Oncol Stem Cell Ther. 2010;3:103–108.
   PubMedGoogle Scholar
• Gabor KM, Schermann G, Lautner-Csorba O, et al. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:622–628.
   PubMed Web of Science ®Google Scholar
• Abraham A, Devasia AJ, Varatharajan S, et al. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Ann Hematol. 2015;94:883–885.
   PubMed Web of Science ®Google Scholar
• Jahns-streubel G, Reuter C, Auf der Landwehr U, et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood. 1997;90:1968–1976.
   PubMed Web of Science ®Google Scholar
• Schröder JK, Kirch C, Seeber S, et al. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol. 1998;103:1096–1103.
   PubMed Web of Science ®Google Scholar
• Abraham A, Varatharajan S, Karathedath S, et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics. 2015;16:877–890.
   PubMed Web of Science ®Google Scholar
• Abraham A, Varatharajan S, Abbas S, et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics. 2012;13:269–282.
   PubMed Web of Science ®Google Scholar
• Jordheim LP, Nguyen-Dumont T, Thomas X, et al. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Drug Metab Dispos. 2008;36:2419–2423.
   PubMed Web of Science ®Google Scholar
• Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: Cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res. 2006;12:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kirch HC, Schroder J, Hoppe H, et al. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol. 1998;26:421–425.
   PubMed Web of Science ®Google Scholar
• Carpi FM, Vincenzetti S, Ubaldi J, et al. CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population. Pharmacogenomics. 2013;14:769–781.
   PubMed Web of Science ®Google Scholar
• Parmar S, Seeringer A, Denich D, et al. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics. 2011;12:503–514.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Laan AC, Vasile E, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids. 2008;27:720–725.
   PubMed Web of Science ®Google Scholar
• Monzo M, Brunet S, Urbano-Ispizua A, CETLAM, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood. 2006;107:4871–4879.
   PubMed Web of Science ®Google Scholar
• Mahfouz RZ, Jankowska A, Ebrahem Q, et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res. 2013;19:938–948.
   PubMed Web of Science ®Google Scholar
• Li X, Shao M, Wang S, et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol. 2014;35:11159–11170.
   PubMed Web of Science ®Google Scholar
• Morrison BA, Davis C, Ucisik-Akkaya E, et al. MHC associations in childhood leukemia: identification of heterozygote advantage. Human Immunol. 2008;69:S96 (abstract 180-P).
   Web of Science ®Google Scholar
• Fitzgerald SM, Goyal RK, Osborne WR, et al. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet. 2006;119:276–283.
   PubMed Web of Science ®Google Scholar
• Caronia D, Martin M, Sastre J, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res. 2011;17:2006–2013.
   PubMed Web of Science ®Google Scholar
• Li H, Wang X, Wang X. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. JBM. 2014;29:e224–e232.
   Web of Science ®Google Scholar
• Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64:3761–3766.
   PubMed Web of Science ®Google Scholar
• Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2007;120:1355–1363.
   PubMed Web of Science ®Google Scholar
• Hunsucker SA, Mitchell BS, Spychala J. The 5’-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther. 2005;107:1–30.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Cros E, Thomas X, et al. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica. 2005;90:1699–1701.
   PubMed Web of Science ®Google Scholar
• Mitra AK, Kirstein MN, Khatri A, et al. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics. 2012;13:1009–1021.
   PubMed Web of Science ®Google Scholar
• Khatri A, Williams BW, Fisher J, et al. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer. 2014;110:304–312.
   PubMed Web of Science ®Google Scholar